Pyridine Derivatives for Selective CB2 Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective compounds that selectively modulate Cannabinoid Receptor 2 (CB2) for treating various diseases such as pain, inflammation, and psychiatric disorders without significant activity on CB1 receptors.
Innovation Solution
Development of specific organic compounds, including 5-(cyclopropylmethoxy)-4-(2,4-dichlorophenyl)-N-[(2S)-1-hydroxy-4-methylpentan-2-yl]pyridine-2-carboxamide and others, which preferentially bind to CB2 receptors with lower CB1 receptor activity, allowing for targeted therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are designed to have high affinity for cannabinoid receptors, then therapeutic efficacy is improved, but selectivity between CB1 and CB2 receptors becomes difficult to achieve
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups at defined positions on the pyridine ring structure. Different substituents (halogens, alkyl groups, alkoxy groups) are placed at specific locations (positions 2, 4, 5, 6) to create localized chemical characteristics that differentiate CB2 affinity from CB1 affinity, enabling selective binding to the desired receptor subtype
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters including substituent type (halogen, alkyl, alkoxy), substituent position on the ring, and N-substituent structure. These parameter modifications allow fine-tuning of the compound's molecular properties to achieve optimal CB2 selectivity while maintaining therapeutic efficacy
2Reliability
If compounds show high activity on CB1 receptors, then pain relief is improved, but side effects increase
Solution Approach 1:
The patent applies the taking out principle by extracting and isolating the pharmacological activity specifically to the CB2 receptor pathway. By designing compounds that selectively target CB2 receptors rather than CB1 receptors, the invention separates the desired therapeutic effects (anti-inflammatory, analgesic) from the harmful side effects associated with CB1 activation (psychoactive effects, cognitive impairment)
3Ease of manufacture
If compound structure is simplified for ease of synthesis, then manufacturing cost is reduced, but selectivity and affinity for CB2 receptors decrease
Solution Approach 1:
The patent applies segmentation by dividing the molecule into distinct functional modules: a core pyridine-2-carboxamide structure, specific substituents at positions 2, 4, and 5, and defined N-substituents. This modular approach allows systematic optimization of each segment's contribution to CB2 binding while maintaining overall structural simplicity for feasible synthesis
Solution Approach 2:
The patent employs universality through the pyridine-2-carboxamide core structure, which serves multiple functions: providing a planar aromatic system for stacking interactions, offering positioned substituents for hydrophobic and electrostatic interactions, and enabling versatile N-substitution patterns. This multi-functional core allows the compound to achieve high CB2 selectivity without requiring overly complex molecular architecture
Data Source
AI summary
The invention relates to compound of formula (I) wherein R1 to R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.